Back HIV Treatment Approved HIV Drugs

Approved HIV Drugs

IAS 2011: Raltegravir Still Effective at 5 Years

The sole approved integrase inhibitor, raltegravir (Isentress), continues to keep HIV suppressed for nearly 5 years in patients starting treatment for the first time, according to astudy presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) last week in Rome.alt

Read more:

Abacavir Looks as Safe and Effective as Tenofovir

A meta-analysis of 28 controlled trials did not find elevated heart attack risk with abacavir, and a Canadian study showed no greater risk of treatment failure among patients with high viral load, according to 2 recently published reports.

The association between use of abacavir (Ziagen, also in the Epzicom and Trizivir coformulations) and myocardial infarction (MI), or heart attack, remains controversial, as does the suggestion that abacavir may not work as well for people who start antiretroviral therapy (ART) with high HIV viral load.

Read more:

FDA Approves Once-Daily Nevirapine

The FDA this week approved a new longer-acting formulation of nevirapine (Viramune XR), enabling once-daily dosing. alt

Read more:

FDA Approves NNRTI Rilpivirine (Edurant, TMC278)

New NNRTI rilpivirine (brand name Edurant, formerly TMC278) received U.S. Food and Drug Administration (FDA) approval Friday for HIV patients starting first-line therapy. alt

Read more:

Once-Daily Elvitegravir Matches Raltegravir in Phase 3 Study

Experimental integrase inhibitor shown non-inferior to raltegravir (Isentress) for treatment-experienced patients, developer reports.

Read more: